Clinical trial · Observational
Quality of Life the Danish Multiple Myeloma Patients
Quality of Life in Danish Multiple Myeloma Patients
NCT02892383CI-TRIAL-00080953QoL-MMcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of the project is to improve quality of life for multiple myeloma patients in the future.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
| Quality of Life | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- A longitudinal description of quality of life (QoL) using patient-reported outcomes measurement (PROM) for the general population of multiple myeloma patients.
- timeFrame
- 24 months
- description
- a. Description of changes in QoL over time
Secondary outcomes (3)
- measure
- Description of changes in QoL over time, based on PROM for the general population of multiple myeloma patients.
- timeFrame
- 24 months
- description
- 1. To analyse changes in QoL measured by EORTC QLQ-C30 (score 0-100), EORTC QLQ-MY20 (score 0-100) and SF12v2-4-week recall (score 0-100) in relation to disease characteristics: * ISS I-III * Type/-s of anti-myeloma treatment * Side-effects of treatment measured by EORTC QLQ-MY20 (score 0-100) and EORTC QLQ-CIPN20 (score 0-100) * Quality of response: IMWG criteria for first and second line treatment 2. To analyse changes in QoL measured by EORTC QLQ-C30 (score 0-100), EORTC QLQ-MY20 (score 0-100) and SF12v2-4-week-recall (score 0-100) in relation to patient characteristics: * Myeloma Frailty score (fit, intermediate-fitness and frail) * Karnofsky Performance score scale (0-100%) * Charlson comorbidity Index (0-33) and Freiburger comorbidity index (0-3)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 110 Years
Show eligibility criteria text
Inclusion Criteria: * Previously untreated or relapsed multiple myeloma patients AND * Treatment demanding multiple myeloma disease Exclusion Criteria: * Inability to understand the Danish language or * Psychic or mental illness that prevents the patient from answering the questions in the questionnaires.
References
Publications (1)
- DERIVEDEngelhardt M, Ihorst G, Singh M, Rieth A, Saba G, Pellan M, Lebioda A. Real-World Evaluation of Health-Related Quality of Life in Patients With Multiple Myeloma From Germany. Clin Lymphoma Myeloma Leuk. 2021 Feb;21(2):e160-e175. doi: 10.1016/j.clml.2020.10.002. Epub 2020 Oct 24. PMID 33218965